Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Genor granted BIOCND development rights to two mAbs. Genor granted BIOCND rights to GB232, an adalimumab biosimilar, in South,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury